EUCTR2011-003570-89-NL
Active, not recruiting
Not Applicable
The effect of interferon beta-1a treatment on functional adaptation in Multiple Sclerosis (MS) - interferon beta-1a and functional adaptation
VU University Medical Center0 sitesNovember 7, 2011
ConditionsMultiple sclerosisMedDRA version: 14.0Level: PTClassification code 10004504Term: Beta interferon therapySystem Organ Class: 10042613 - Surgical and medical proceduresTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
DrugsRebif
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Multiple sclerosis
- Sponsor
- VU University Medical Center
- Status
- Active, not recruiting
- Last Updated
- 14 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •RRMS or relapsing SPMS
- •Meet safety criteria for MRI
- •Group 1: Subjects affected by RRMS starting or recently started with Interferon beta\-1a treatment
- •Group 2: Subjects affected by relapsing SPMS on interferon beta\-1a treatment.
- •Group 3: Untreated Subjects affected by RRMS or relapsing SPMS
- •Group 4: Healthy controls
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 100
Exclusion Criteria
- •MS other than RRMS or relapsing SPMS
- •presence or history of psychiatric disease
- •presence or history of neurological disease
- •presence or history of alcohol or drug abuse
- •presence of contra\-indications for MRI
- •presence of contra\-indications for Rebif
- •Use of immunosupressive agents
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
Comparison of Interferon-beta-1a and Dexamethasone on hospitalized patients with Covid-19.IRCT20150622022869N9Yasouj University of Medical Sciences176
Recruiting
Phase 3
Efficacy and safety of Interferon beta-1-a in mild to moderate COVID-19IRCT20120703010178N25Shahid Beheshti University of Medical Sciences100
Completed
Not Applicable
The effect of interferon beta-1a treatment on functional adaptation in Multiple Sclerosis (MS)MSmultiple sclerosis1000381610012303NL-OMON35491Vrije Universiteit Medisch Centrum22
Recruiting
Phase 3
ReciGen for treatment of Covid-19Covid 19.COVID-19, virus identifiedU07.1IRCT20150914024017N1Tehran University of Medical Sciences40
Recruiting
Phase 2
effect of Interfron-beta1(zifron) on clinical improvement and prognosis of COVID-19 in Tabriz Imam-Reza hospitalIRCT20200406046968N3Zist Daru Danesh Company60